Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy

BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yoshida, Eric M, Sherman, Morris, Bain, Vincent G, Cooper, Curtis L, Deschênes, Marc, Marotta, Paul J, Lee, Samuel S, Krajden, Mel, Witt-Sullivan, Helga, Bailey, Robert J, Usaty, Christopher, Peltekian, Kevork
Format: Artigo
Idioma:Inglês
Publicat: Pulsus Group Inc 2009
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2694653/
https://ncbi.nlm.nih.gov/pubmed/19319382
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars